Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering

Keyphrases

• IgG Antibody 100%
• Serum Half-life 100%
• Fc Variants 100%
• Therapeutic IgG 100%
• Fc Engineering 100%
• PH Dependence 66%
• Fc Region 66%
• IgG Fc 66%
• Dissociation 33%
• Wild Mice 33%
• Endothelial Cells 33%
• Pharmacokinetic Profile 33%
• Infectious Diseases 33%
• Human Serum 33%
• In Vivo Model 33%
• Autoimmune Disease 33%
• Intracellular Trafficking 33%
• Instantaneous Rate 33%
• Lysosome 33%
• Neutral pH 33%
• Endosome 33%
• Therapeutic Antibody 33%
• In Vitro Techniques 33%
• Human Trials 33%
• Cynomolgus Monkey 33%
• Equilibrium Binding Constant 33%
• Humanized Mice 33%
• Recycling Mechanism 33%
• FcRn 33%
• FcRn Binding 33%
• Intracellular Recycling 33%
• Scarlet 33%
• FcRn Transgenic Mice 33%

Immunology and Microbiology

• Immunoglobulin G 100%
• Plasma Half Life 100%
• Binding Affinity 50%
• Serum (Blood) 50%
• Autoimmune Disease 50%
• Wild Type Mouse 50%
• Transgenic Mouse 50%
• Intracellular Trafficking 50%
• Pharmacokinetics 50%
• Internalization 50%
• Lysosome 50%
• Infectious Disease 50%
• Endosome 50%
• Humanized Mouse 50%
• Macaca fascicularis 50%
• Therapeutic Antibodies 50%
• Blood pH 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunoglobulin G 100%
• Malignant Neoplasm 50%
• Infection 50%
• Wild Type Mouse 50%
• Autoimmune Disease 50%
• Clinical Trial 50%
• Transgenic Mouse 50%
• Macaca fascicularis 50%
• Pharmacokinetics 50%